Each gram of Hytone® (hydrocortisone) Cream 2½% contains 25 mg of hydrocortisone in a water-washable base of purified water, propylene glycol, glyceryl monostearate SE, cholesterol and related sterols, isopropyl myristate, polysorbate 60, cetyl alcohol, sorbitan monostearate, polyoxyl 40 stearate and sorbic acid. Each mL of Hytone (hydrocortisone) Lotion 2½% contains 25 mg of hydrocortisone in a vehicle consisting of carbomer 940, propylene glycol, polysorbate 40, propylene glycol stearate, cholesterol and related sterols, isopropyl myristate, sorbitan palmitate, cetyl alcohol, triethanolamine, sorbic acid, simethicone, and purified water.
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Media Articles Related to Hytone ( Topical)
First topical pharmacologic therapy to enter clinical trials for "double chin"
Source: Clinical Trials / Drug Trials News From Medical News Today [2013.11.22]
Topokine Therapeutics has initiated dosing in a Phase 2, randomized controlled clinical trial of XAF5 Gel for reduction of excess submental fat, commonly known as "double chin." XAF5 Gel is a proprietary skin formulation of a compound already known to reduce fat around the human eye. Study participants are applying XAF5 Gel or placebo once a night to skin under the chin.
FDA Warns of Infection Risk With Topical Antiseptics
Source: MedPage Today Surgery [2013.11.14]
WASHINGTON (MedPage Today) -- The FDA wants label and packaging changes for certain topical antiseptic products to reduce the risk of infection.
FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Source: MedicineNet brimonidine Specialty [2013.08.28]
Title: FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Category: Health News
Created: 8/27/2013 12:35:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
Actelion launches VALCHLOR (mechlorethamine) gel 0.016% in the US
Source: Dermatology News From Medical News Today [2013.11.20]
Actelion (SIX: ATLN) has announced that VALCHLOR™ (mechlorethamine), the first and only FDA-approved topical formulation of mechlorethamine, is now available for patients in the United States (US).
Published Studies Related to Hytone ( Topical)
Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in
patients receiving botulinum toxin therapy. 
as a potential new therapy in BSP... CONCLUSIONS: Topical AH8 is safe and promising for
Instant dentin hypersensitivity relief of a single topical application of an
in-office desensitizing paste containing 8% arginine and calcium carbonate: A
split-mouth, randomized-controlled study. 
Abstract Objective. The aim of this study was to evaluate the clinical efficacy
of an in-office desensitizing paste containing 8% arginine and calcium carbonate
relative to calcium carbonate alone in the reduction of dentin hypersensitivity
in a randomized, double-blind, split-mouth clinical trial...
Effect of subgingival application of topical ozonated olive oil in the treatment
of chronic periodontitis: a randomized, controlled, double blind, clinical and
microbiological study. 
CONCLUSION: The OZO, as an adjunctive therapy as well as a mono-therapy is
Topical capsaicin (low concentration) for chronic neuropathic pain in adults. 
CONCLUSIONS: There were insufficient data to draw any conclusions about
Treatment for postoperative wound pain in gynecologic laparoscopic surgery:
topical lidocaine patches. 
CONCLUSIONS: Topical lidocaine patches at the laparoscopic port sites reduced
Clinical Trials Related to Hytone ( Topical)
Adherence to Topical Hydrocortisone 17-Butyrate 0.1% (LocoidŽ) Using Different Vehicles in Adults With Atopic Dermatitis [Active, not recruiting]
The purpose of this research study is to better understand how the study drug Locoid works
when people use it to treat atopic dermatitis.
Contribution of Salivary Cortisol in the Detection of Infra-clinic Cortisol Adenoma (ACIC) [Recruiting]
Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency [Not yet recruiting]
Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement
dose in conditions of physical or psychological stress to prevent life threatening adrenal
crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e. g.
gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone
dose is crucial. The study is conducted to offer patients the possibility to perform
hydrocortisone self administration in emergency situations in a way of administration which
is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of
subcutaneous hydrocortisone administration will be studied and compared to intramuscular
Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration [Recruiting]
The current study will test the causal relationship between elevated levels of cortisol and
the serotonin transporter gene (5-HTTLPR) as these factors influence sensitivity to
environmental threat. The investigators predict that carriers of the short allele of the
serotonin transporter gene who have elevated cortisol levels will be most sensitive to
threatening environments, whereas carriers of the long allele who do not have elevated
cortisol (placebo subjects) will be least sensitive.
Trial of Hydrocortisone for Post-Traumatic Stress Disorder (PTSD) [Recruiting]
Developing novel and effective pharmacologic interventions for this post-traumatic stress
disorder is important. The investigators propose to replicate findings of an earlier
published pilot study using low dose hydrocortisone as a treatment for PTSD. In order to do
so in a more meaningful way, the investigators will conduct a larger but similar randomized
double-blind placebo-controlled, cross-over design treatment study examining the use of low
dose hydrocortisone (or placebo) for 4 weeks in combat veterans suffering from PTSD.
The investigators hypothesize that, as described by Aerni et al. (2004), administration of
daily hydrocortisone will lead to a reduction in PTSD symptom severity, but particularly for
re-experiencing types (e. g., flashbacks, nightmares)of symptoms. The investigators also hope
to examine potential predictors and moderators of treatment response based on subjects'
clinical characteristics, as well as serum cortisol and ACTH levels.